IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3021% above fair value
$0.18−0.01 (-7.24%)
Close on Nov 12, 2026Market cap $19.07MP/E –Yield –
IGC Pharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
IGC Pharma's profit margin for the twelve months ending Jun 30, 2026 was -702.1%. For fiscal 2025 it was -560.3%, against -966.5% the year before. The highest annual figure on record is -28.0% in fiscal 2013.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | -560.3% | +406.2 |
| FY2024 | Mar 31, 2024 | -966.5% | +296.5 |
| FY2023 | Mar 31, 2023 | -1263.0% | +2519.4 |
| FY2022 | Mar 31, 2022 | -3782.4% | −2801.2 |
| FY2021 | Mar 31, 2021 | -981.2% | −801.5 |
| FY2020 | Mar 31, 2020 | -179.6% | −99.6 |
| FY2019 | Mar 31, 2019 | -80.1% | +1.4 |
| FY2018 | Mar 31, 2018 | -81.4% | +240.3 |
| FY2017 | Mar 31, 2017 | -321.7% | −277.6 |
| FY2016 | Mar 31, 2016 | -44.1% | +16.0 |
| FY2015 | Mar 31, 2015 | -60.1% | +72.9 |
| FY2014 | Mar 31, 2014 | -133.0% | −104.9 |
| FY2013 | Mar 31, 2013 | -28.0% | +156.5 |
| FY2012 | Mar 31, 2012 | -184.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -1107.9% | −620.4 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -757.7% | −394.7 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -207.4% | +504.2 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -953.4% | −536.7 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -487.5% | +386.8 |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -363.0% | +614.9 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -711.7% | +2028.0 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -416.7% | +425.5 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -874.3% | −500.4 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -978.0% | +1449.7 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -2739.7% | −2062.3 |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -842.3% | +366.6 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -373.9% | +939.8 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -2427.7% | +2902.6 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -677.4% | +999.4 |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -1208.9% | +6548.2 |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -1313.7% | +1008.4 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -5330.3% | −1689.6 |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -1676.8% | +474.2 |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -7757.1% | −6431.5 |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -2322.1% | −1999.8 |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -3640.7% | +7235.1 |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -2150.9% | −1871.2 |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -1325.6% | −1260.9 |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -322.3% | −238.6 |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -10875.9% | −10773.5 |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -279.8% | −190.4 |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -64.7% | +41.2 |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -83.6% | −49.0 |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -102.3% | −52.0 |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -89.3% | −19.4 |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -105.9% | +23.4 |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -34.6% | +781.9 |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -50.4% | +764.3 |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -69.9% | −25.2 |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -129.4% | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -816.5% | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -814.6% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -44.7% | – |
See a number that looks wrong?